Results 141 to 150 of about 37,288 (269)

Services trade and domestic regulation [PDF]

This paper argues that regulatory measures affect the fixed cost of entering a market as well as the variable costs of servicing that market. Moreover, differences in regulation among countries often imply that firms have to incur entry costs in every ...
Kox, Henk L.M., Nordås, Hildegunn Kyvik
core   +1 more source

Operationalizing BioSSbD: A safe‐and‐sustainable‐by‐design framework for biorefineries

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract Biorefineries are central to the transition toward a circular bioeconomy; however, their increasing scale and technological heterogeneity, and the integration of biological, chemical, and thermochemical processes introduce complex challenges related to safety, sustainability, and operational reliability. Existing Safe‐and‐Sustainable‐by‐Design
Fernando Ramonet
wiley   +1 more source

The ⁶⁸Ge/⁶⁸Ga generator for enhancing productivity and reducing costs in nuclear medicine: experience from a university hospital. [PDF]

EJNMMI Radiopharm Chem
Guercio A, Martin T, Migliari S, Gagliardi A, Scarlattei M, Baldari G, Martelli N, Ruffini L.   +7 more
europepmc   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Phare Programme and Contract Information, 1996 Latvia [PDF]

, 1996

core  

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Building trust in the integration of artificial intelligence into chemical risk assessment: findings from the 2024 ECETOC workshop. [PDF]

Arch Toxicol
Gant TW, Boxall A, Burgwinkel D, Zare Jeddi M, Djidrovski I, Friedrichs S, Hardy B, Hartung T, Holland D, Karwath A, Kienhuis A, Kleinstreuer N, Lin Z, Marczylo EL, Marvuglia A, Qian H, van Ravenzwaay B, Rees P, Sarimveis H, Tralau T, Wilmot L, Zalewski A, Rouquié D.   +22 more
europepmc   +1 more source

Migrating longitudinal African mental health data from staging to the OMOP common data model within the INSPIRE network datahub. [PDF]

Front Psychiatry
Bhattacharjee T, Mugotitsa B, Ochola M, Momanyi R, Andeso P, Amadi D, Mailosi D, Najjemba L, Greenfield J, Mabe K, Slaymaker E, Todd J, Kiragga A, INSPIRE Network .   +13 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Personalised Psychological Care in Hospitals: An Organisational Model of Integrated, Patient- and Staff-Centred Services (2019-2024). [PDF]

J Pers Med
Chieffo DPR, Massaroni V, Delle Donne V, Lafuenti L, Monti L, Arcangeli V, Moriconi F, Ferrarese D, Galluzzi R, Mercuri EM, Sani G, Tortora G, Gasbarrini A.   +12 more
europepmc   +1 more source